SCHEMBL2820260

SCHEMBL2820260

CCCCc1ccccc1Oc1ccc([N+](=O)[O-])cc1S(=O)(=O)N1CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 7/20 0.45
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 5/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HPGD P15428 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.39
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2C9 P11712 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2821044 0.83 TBXA2R (0.53) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2820383 0.83 KMT2A (0.55) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2820557 0.82 TBXA2R (0.53) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2822209 0.82 TBXA2R (0.45) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2820494 0.81 HSPB1 (0.54) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2820982 0.80 KMT2A (0.49) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2823731 0.80 KMT2A (0.43) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2819545 0.80 L3MBTL1 (0.54) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2821067 0.79 PKM (0.43) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL2820127 0.79 ALDH1A1 (0.49) TBXA2RL3MBTL1ALDH1A1NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1849469-B1 Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS INC (US) 2010-10-27 EP claimed
US-7700586-B2 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS, INC. (US) 2010-04-20 US claimed
US-8242118-B2 Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS INC. (US) 2012-08-14 US disclosed
US-20100204213-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS BAYER HEALTHCARE AG (DE) 2010-08-12 US disclosed
US-7700586-B2 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders AXIKIN PHARMACEUTICALS, INC. (US) 2010-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204213-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS CCR3, CCR1, CCR2 TBXA2R 1120/4885L3MBTL1 4577/4885ALDH1A1 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.